Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Two common biologic therapies for lupus — rituximab and belimumab — appear to be equally effective at keeping the disease in check, according to a new UK study. Both drugs led to similar rates of low disease activity after adjustment, though belimumab showed better drug survival when used as a second-line treatment. Researchers say direct comparative trials are still needed to guide treatment decisions.
A new observational study out of Cambridge, UK, finds that rituximab and belimumab — two widely used biologic therapies for systemic lupus erythematosus (SLE) — perform similarly when it comes to achieving low disease activity. The study tracked 176 SLE patients over several years, comparing outcomes across 175 rituximab and 58 belimumab treatment courses.
After statistical adjustment, neither drug had a clear edge in helping patients reach the primary goal: a low disease activity score paired with a reduced steroid dose. Both treatments also led to meaningful declines in disease activity and prednisolone use over time, with comparable effects on kidney function and lupus-related organ damage.
There was one notable difference: when used as a second-line or later biologic therapy, belimumab was associated with better drug survival than rituximab — meaning patients stayed on it longer. For first-line use, however, the two were comparable.
Key Takeaways:
Why it matters: With no head-to-head randomized trials to guide clinicians, SLE treatment decisions often rely on observational data like this. These findings suggest neither drug is universally superior, reinforcing the need for personalized treatment approaches — and better-designed comparative studies.
